Other

2019 Subject Index

J Clin Res Pediatr Endocrinol 2019;11(4):0-0

1α hydroxylase........................................................................34
21-hydroxylase deficiency.......................................................41
25-hydroxyvitamin D.............................................................220
25(OH) vitamin D..................................................................181
46,XX disorders of sex development...............................24, 196
ABCC8 mutation......................................................................82
Acid-labile subunit deficiency................................................432
Adolescent.............................................................................247
Adolescent beliefs..................................................................118
Adult height...........................................................................234
AGPAT2..................................................................................319
ALPL gene.............................................................................306
AMH......................................................................................287
Androgen insensitivity syndrome............................................24
Androgen receptor gene mutations.........................................24
Antithyroid drug....................................................................165
Aromatase deficiency............................................................196
Asthma..................................................................................270
Auto-antigen............................................................................55
Autoimmune thyroiditis.........................................................132
Berardinelli-Seip syndrome....................................................319
Biomarker.............................................................................157
Birth weight...........................................................................125
Body cell mass................................................................46, 366
Bone density.........................................................................439
Bone turnover.......................................................................110
Borjeson-Forssman-Lehmann syndrome................................419
Brain injury...........................................................................374
Cabergoline...........................................................................150
Cardiovascular risk................................................................262
Carotid intima media thickness...............................................61
Central precocious puberty....................................................227
Child......................................................................................262
Childhood..............................................................................247
Children..........82, 132, 150, 157, 189, 202, 350, 374, 395, 410
Cholesterol............................................................................270
Cleidocranial dysplasia..........................................................301
Clinical management.............................................................400
Clinical phenotype...................................................................24
Congenital adrenal hyperplasia....................................14, 41, 61
Congenital generalized lipodystrophy....................................319
Congenital hyperinsulinism.............................................82, 400
Congenital hypothyroidism....................................................240
Congenital portosystemic venous shunt syndrome  207
Continuous glucose monitoring.............................................189
Cord blood............................................................................125
CYP19A1 gene.......................................................................196
CYP27B1 gene.........................................................................34
Cystatin C................................................................................46
Deficiency.............................................................................220
Delayed puberty....................................................................444
Diabetes team.........................................................................70
Diabetic nephropathy............................................................157
Diagnosis..................................................................................4
Diastolic function....................................................................61
Diazoxide..............................................................................219
Disorder of sexual differentiation..........................................211
Duplication............................................................................306
Early......................................................................................341
Early menarche.....................................................................234
Echocardiography....................................................................61
Education..............................................................................189
Enzyme replacement therapy................................................306
Epicardial fat thickness............................................................61
Estradiol................................................................................388
Estrogen................................................................................395
Etidronate.............................................................................311
Family conflict.......................................................................118
Fat biology.............................................................................319
Final adult height...................................................................227
GALNT3...................................................................................94
Gene mutation.......................................................................400
Generalized arterial calcification............................................311
Genetic testing........................................................................88
Genotype.................................................................................41
GH therapy............................................................................253
GH1.......................................................................................426
Glomerular filtration rate.........................................................46
Glucose..................................................................................125
Glucose metabolism..............................................................350
Glycated hemoglobin.............................................................350
Glycemic variability...............................................................189
Graves’ disease......................................................................165
Growth..................................................................................104
Growth hormone...................................................................426
Growth hormone deficiency..................................253, 329, 419
Growth hormone therapy......................................................329
Growth hormone treatment...................................................350
Gynecomastia........................................................................388
Haemophilia..........................................................................173
Hashimoto’s thyroiditis..........................................................410
Hashitoxicosis.......................................................................165
HbA1c.............................................................................70, 358
Hyperlipidemia......................................................................366
Hyperparathyroidism..............................................................88
Hyperphosphatemia................................................................94
Hypertension.........................................................................173
Hyperthyroidism...................................................................207
Hypogonadism...............................................................110, 419
Hypogonadotrophic hypogonadism.......................................444
Hypophosphatasia.................................................................306
Hypophysis...............................................................................4
Hypothalamus...........................................................................4
IGF1/IGFBP3 molar ratio........................................................253
IGFALS gene mutation...........................................................432
Impaired hypoglycemia awareness........................................189
Impaired liver enzymes.........................................................366
Inappropriate antidiuretic hormone syndrome � 202
Infancy..................................................................................287
Infant....................................................................................311
Inherited 1q deletion...............................................................88
Insulin...................................................................................125
Insulin resistance...................................................262, 270, 366
Insulin sensitivity..................................................................350
Insulin treatment...................................................................278
Insulin-like growth factor type-1............................................293
Insulin-like growth factor type-1 receptor..............................293
Intrauterine discordancy........................................................293
Isolated growth hormone deficiency......................................426
Jordan...................................................................................358
Kabuki syndrome..................................................................219
Ketoacidosis..........................................................................374
KISS1R..................................................................................444
Kisspeptin.............................................................................444
KNHANES..............................................................................234
Left ventricular function..........................................................61
Left ventricular mass index.....................................................61
Leuprolide acetate.................................................................227
Leydig cell hypoplasia............................................................211
LHCGR gene..........................................................................211
Lipid......................................................................................270
Lipoprotein............................................................................270
Liver......................................................................................395
Macroadenomas....................................................................150
Magnesium............................................................................311
Marrow expansion.................................................................110
McCune-Albright syndrome...................................................100
Meta-analysis...........................................................................55
Metabolic control...................................................................358
Metabolic syndrome......................................................173, 262
Microadenomas.....................................................................150
Mini-puberty..........................................................................287
Mitral deceleration time..........................................................61
MMP......................................................................................157
MODY.....................................................................................82
Monitoring.............................................................................227
Mosaicism...............................................................................24
Mutation................................................................................439
Myocardial function...............................................................410
Neonatal cholestasis..............................................................100
Neonatal hypopituitarism..........................................................4
Neonatal screening program..................................................240
Neuron-specific enolase.........................................................374
Newborn...............................................................................240
Newborn screening.................................................................14
NHANES................................................................................270
Non-compliance....................................................................118
Novel mutations....................................................................341
Novel variants.......................................................................211
Nutrition................................................................................141
Nutritional thrift....................................................................449
Obesity......................................46, 76, 173, 234, 247, 262, 270
Onset....................................................................................341
Osteoclast.............................................................................439
Osteopetrosis........................................................................439
Osteoporosis.........................................................................110
Over-the-counter drugs..........................................................141
Overweight............................................................................247
Paediatrics.....................................................................219, 329
Pericardial effusion................................................................219
Perinatal form.......................................................................306
PHF6.....................................................................................419
Pituitary................................................................................150
Polymorphisms.......................................................................55
Polyneuropathy.....................................................................319
Postnatal growth....................................................................293
Postnatal weight gain.............................................................449
Prader-Willi syndrome...........................................................253
Precocious puberty................................................................100
Premature thelarche..............................................................287
Prematurity...........................................................................104
Prevalence...............................................................................76
Primary IGF-1 deficiency.......................................................432
Primary school children........................................................181
Prolactin................................................................................150
Prostaglandin I2....................................................................207
Pubertal progression..............................................................227
Puberty.................................................................................388
Pulmonary arterial hypertension...........................................207
Radioactive iodine.................................................................165
Random luteinizing hormone................................................227
Ratio......................................................................................388
Renal injury...........................................................................262
Resistance.............................................................................118
rhGH treatment.....................................................................419
Rickets..................................................................................141
Risk factors............................................................................247
RUNX2..................................................................................301
S100B....................................................................................374
Scale development................................................................278
School age children.................................................................76
Sclerosis................................................................................439
Second-tier..............................................................................14
Seipinopathy.........................................................................319
Self-management..................................................................278
Serum uric acid concentration...............................................262
Severe obesity.......................................................................341
Severe short stature...............................................................301
Shear wave elastography.......................................................132
Short stature..................................................234, 329, 426, 432
Signs of Y-chromosomal influence...........................................88
Small for gestational age.......................104, 253, 293, 329, 449
Socioeconomic status............................................................358
Speckle tracking echocardiography.......................................410
Steroid...................................................................................141
Steroid profiling.......................................................................14
Stoss therapy.........................................................................141
Surgery..................................................................................150
Telehealth................................................................................70
Term newborn.........................................................................41
Testosterone..........................................................................388
Thalassemia major................................................................110
Thyroid..................................................................................132
Thyroid hormones.................................................................240
Thyrotoxicosis.......................................................................165
TIMP.....................................................................................157
Tolvaptan...............................................................................202
Total thyroidectomy...............................................................165
Treatment..........................................................................4, 311
Tri-ponderal mass index........................................................366
Tumoral calcinosis...................................................................94
Turkey.....................................................................................76
Turner syndrome.....................................................88, 329, 395
Type 1 diabetes.................................55, 70, 118, 189, 278, 358
Type 1 diabetes mellitus................................................157, 374
Vaspin...................................................................................125
Vitamin D........................................................................34, 220
Vitamin D deficiency.............................................................181
Vitamin D dependent rickets...................................................34
Vitamin D insufficiency.........................................................181
Vitamin D levels....................................................................181
Wheezing..............................................................................270
X-inactivation........................................................................419
Zinc transporter 8 autoantibody..............................................55